Welcome
Action number CA17138 brings together Chronic GvHD (cGvHD) researchers across Europe for the first time, creating a network of cross-disciplinary experts in the field.
We aim to link research groups, clinical teams and industry partners throughout Europe to enable a breakthrough in scientific developments, leading to new concepts for improving the survival and quality of life of transplant patients.
About this Action
COST Action Integrated European Network on Chronic Graft Versus Host Disease (cGvHD) (EUROGRAFT) CA17138
Introduction to the Action
The Action will lead to an improved understanding of the pathogenesis of cGvHD and its associated comorbidities, and will develop a coordinated approach to therapy, strengthening European research and innovation via collaboration.
Countries taking part
Please see map showing the geographical spread of EuroGraft participating countries. We welcome new countries to join us.
If you would like for your country to be involved in the Action, please follow the link below to see how you can participate.
United Kingdom
-
Dr Shaheda Ahmed
-
Dr Xiao-Nong Wang
-
Dr Rachel Crossland
-
Prof. Anne Dickinson
Germany
-
Prof Gabriele Multhoff
-
Ulrike Koehl
-
Robert Zeiser
-
Daniel Wolff
Italy
-
Prof Sara Galimberti
-
Atillio Olivieri
-
Prof Chiara Bonini
Poland
-
Prof Katarzyna Bogunia-Kubik
France
-
Dr Nuala Mooney
-
Prof Gerard Socie
Portugal
-
Dr Jose Silvestre Serra Da Silva
Croatia
-
Magdalena Grce
-
Drazen Pulanic
Austria
-
Dr Alexander Deutsch
-
Dr Anita Lawitschka
-
Prof. Hildegard Greinix
Belgium
-
Dr Philippe Lewalle
-
Dr Hélène Schoemans
Bosnia and Herzegovina
-
Mr Josip Petrovic
Bulgaria
-
Prof Milena Ivanova-Shivarova
-
Dr Maya Yordanova
Finland
-
Dr Satu Koskela
-
Prof Jukka Partanen
Hungary
-
Dr Miklós László Udvardy
-
Dr Hajnalka Andrikovics
Norway
-
Prof Frode Jahnsen
-
Prof Marit Inngjerdingen
-
Prof Lisbet Sviland
Serbia
-
Dr Emina Milosevic
-
Dr Vladimir Perovic
Spain
-
Dr Anna Barata
-
Antonio Pérez Martínez
Switzerland
-
Dr Jörg Halter
![]()
Estonia
-
Dr Eric Tkaczyk
Czech Republic
-
Dr Marie Lipoldova
Ireland
-
Dr Günther Eissner
Sweden
Intention to join Action - in process
Turkey
-
Dr Serap Evran
Greece
-
Dr Eleni Gavriilaki
Netherlands
Intention to join Action - in process
Denmark
-
Dr Lars Klingen Gjærde
Meet our working groups
Epidemiology
The development of an epidemiological platform on cGvHD within EUROGRAFT is a novel approach tounderstanding the disease incidence and associated comorbidities. Results of the analysis will enablea deeper understanding of the incidence of the disease and enable additional data to be included in current European wide databases for use in future clinical trials.
Biomarkers
This Working Group will assess the type and amount of biomarker information which is currently available in the literature and assess those which are worthy of further validation and study.
Socioeconomics/Quality of life
CGvHD is a long term complex disease which has several co-morbidities and as such impacts on the quality of life of patients. By studying the societal impact of the disease via documented quality of life assessments, including reduced working days due to hospital stays, EUROGRAFT will allow an improved assessment of the burden on society of cGvHD at both the individual and European level.
NIH Consensus
The NIH consensus criteria needs to be implemented uniformly if diagnosis and treatment of
cGVHD is to be optimized. The aim of this Working Group will be to aid in both the understanding and
implementation of the NIH Consensus via Training Schools and workshops.
Immunotherapy
Patients with cGvHD (30-50%) can become refractory to standard therapy, new treatment options and the assessment of current novel therapies are urgently needed to improve the long term outcome and quality of life. In this Working Group the Action will bring together experts in cGVHD and clinical trial development, especially in the realm of cellular therapies with the aim of developing concepts for new approaches including personalized approaches to therapy.
